Basics |
CRISPR Therapeutics AG
CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics.
|
IPO Date: |
October 19, 2016 |
Sector: |
Healthcare |
Industry: |
Biotech |
Market Cap: |
$3.27B |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$1.63 | 2.81%
|
Avg Daily Range (30 D): |
$1.16 | 3.23%
|
Avg Daily Range (90 D): |
$1.07 | 2.67%
|
Institutional Daily Volume |
Avg Daily Volume: |
1.1M |
Avg Daily Volume (30 D): |
1.93M |
Avg Daily Volume (90 D): |
1.96M |
Trade Size |
Avg Trade Size (Sh.): |
64 |
Avg Trade Size (Sh.) (30 D): |
63 |
Avg Trade Size (Sh.) (90 D): |
65 |
Institutional Trades |
Total Inst.Trades: |
5,187 |
Avg Inst. Trade: |
$2.73M |
Avg Inst. Trade (30 D): |
$2.51M |
Avg Inst. Trade (90 D): |
$2.3M |
Avg Inst. Trade Volume: |
.04M |
Avg Inst. Trades (Per Day): |
3 |
Market Closing Trades |
Avg Closing Trade: |
$4.87M |
Avg Closing Trade (30 D): |
$5.45M |
Avg Closing Trade (90 D): |
$5.41M |
Avg Closing Volume: |
72.98K |
|
|
|
|
Financials |
|
TTM |
Q4 2024 |
FY 2024 |
Basic EPS
|
$-4.34
|
$-.42
|
$-4.34
|
Diluted EPS
|
$-4.34
|
$-.42
|
$-4.34
|
Revenue
|
$ 37.31M
|
$ 35.69M
|
$ 37.31M
|
Gross Profit
|
$
|
$
|
$
|
Net Income / Loss
|
$ -366.25M
|
$ -37.31M
|
$ -366.25M
|
Operating Income / Loss
|
$ -466.57M
|
$ -64.59M
|
$ -466.57M
|
Cost of Revenue
|
$
|
$
|
$
|
Net Cash Flow
|
$ -91.27M
|
$ 72.67M
|
$ -91.27M
|
PE Ratio
|
|
|
|
|